Drug Combination Details
| General Information of the Combination (ID: C40950) | |||||
|---|---|---|---|---|---|
| Name | Daunorubicin NP Info | + | NL-101 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| MOLM-13 | CVCL_2119 | Adult acute myeloid leukemia | Homo sapiens | |||
| THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
| HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | |||
| Kasumi-1 | CVCL_0589 | Acute myeloid leukemia | Homo sapiens | |||
| NOMO-1 | CVCL_1609 | Adult acute monocytic leukemia | Homo sapiens | |||
| OCI-AML-2 | CVCL_1619 | Adult acute myeloid leukemia | Homo sapiens | |||
| OCI-AML-3 | CVCL_1844 | Adult acute myeloid leukemia | Homo sapiens | |||
| Experimental
Result(s) |
NL 101 in combination with daunorubicin could be an alternative novel therapeutic strategy for treating leukemia. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Novel SAHA?bendamustine hybrid NL?101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia. Oncol Rep. 2020 Jul;44(1):273-282. | |||
